Skip to main content

Companion Diagnostic Market is Growing Dynamically at a Trendy CAGR of 15.4% During Forecast to 2023


Market Scope:
Companion diagnostics (CDx) are assaysor medical devices which provides information on the safe consumption or use of a drug or biological product. The test can determine the compatibility of the drug with the patient. Personalized medicine has pushed such devices to the forefront with many patients opting for this safe service to nullify side-effects of any drugs. Market Research Future (MRFR) asserts in its latest companion diagnostic market report the various developments and trends which can take place during the period of 2018 to 2023 (forecast period).
The global Companion Diagnostic Market Growth is set to touch a valuation of USD 12,647.5 million by 2023. It is pegged to display a CAGR of 15.4% over the forecast period. High costs of drug discovery and drug development is the primary factor driving market growth. CDx devices can provide vital information on the safety of drugs with respect to the individual. The use of these devices by pharmaceutical companies for improving the clinical outcomes of new drugs can positively impact the market.
Improving the validity and accuracy of biomarkers for identifying cancerous cells can also fuel market growth. The adoption of personalized medicine and chances of improving patient outcomes that can lower healthcare costs and minimize drug use can have a positive impact on the global companion diagnostic market.
However, the concerns over inaccuracy of test results may impede the market growth.
Competition Outlook:
F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Qiagen N.V., Agilent Technologies, ARUP Laboratories, Abbott Laboratories, and Myriad Genetics, Inc.
Segmentation:
·         The global companion diagnostics marketreport is segmented by technology, application, and end user.
·         By technology, it has been segmented into polymerase chain reaction (PCR), in-situ hybridization, and immunohistochemistry. In-situ hybridization is a method in which modified DNA or RNA strands are used to localize a particular group of DNA or RNA in a section of the tissue. It can reveal the location of specific chromosomes, which can be used to target specific group of cells without affecting the neighboring cells. Immunohistochemistry is an examination for identification of carcinomas of unknown primary site (CUP). It can be used in identification and classification of cancerous cells in the body.
·         Applications in the companion diagnostics market comprise as central nervous system disorders, cancer, infectious diseases, cardiovascular diseases, and others.  Cancer is a disease which is accountable for many deaths annually. Companion diagnostics falls under pharmacogenomics which uses the genetic makeup of an individual for creating drugs suited for that individual. The success of personalized medicine using CDx assays as a base for identification of such traits can bode well for the market. Neurological disorders have a genetic disposition and scientists are redoubling their efforts at creating effective biomarkers for treating disorders such as Alzheimer’s.
·         By end user, the companion diagnostics market caters to clinical laboratories, contract research organizations, pharma & biotech companies, and others.
Regional Analysis:
The global companion diagnostics market, based on region, is divided into the Americas, Europe, AsiaPacific (APAC), and the Middle East & Africa (MEA).
The Americas can continue to dominate the global companion diagnostics market. Within the region, North America can lead mainly due to an established healthcare system and technological advancement in drugs. Presence of large number of players has led to collaborations and partnerships between pharmaceutical companies and firms specializing in companion diagnostics.
Europe has assumed the second-largest position in the market. Focus on improving imaging and assays for chronic diseases as well as focus on targeted therapies for oncology can induce demand in the global companion diagnostic market. Germany and the U.K. are expected to be the biggest revenue generators of the region.
 NOTE : Our team of researchers are studying Covid19 and its impact on various industry         verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.


Labels:

Comments

Post a Comment

Popular posts from this blog

Covid 19 Analysis on Medical Devices and Accessories Market is Growing at a Healthy CAGR of 6.53% During Forecast to 2023

Market Insights: Medical devices and accessories refer to any apparatus, machine, instrument used for the treatment of disease and illness through monitoring, diagnosis, and treatment. Growing occurrences of chronic diseases and diabetes, geriatric population, rising cases of surgical cases, healthcare expenditure, and technological advancements for superior medical infrastructures, and constant investments by industry giants are some of the pointers that might help the global medical device and accessories market to flourish during the forecast period. Market Research Future stated that the global Covid 19 Analysis on Medical Devices and Accessories Market Growth is estimated to register a CAGR of 6.53%, reaching the valuation of USD 133,835.9 , during the forecast period, 2014-2023 . Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/5466 Other additional factors influencing the growth of the global market include mergers and collaboration led by the...
Post a Comment
Read more

BRIC Diabetes Treatment and Prevention Market is Supposed to Gain at a Fruitful CAGR of 11.52% During Forecast to 2023

Market Highlights Diabetes drugs are the drugs which are administered for the treatment of different types of Diabetes. The prevalence of diabetes is on the rise due to increased life expectancy, changing lifestyles, and the rising incidence of obesity. Diabetes can be kept in control with the help of medication, exercise and controlled diet.  Diabetes Prevention Industry in BRICS is expected to reach  USD 9.45 billion  by 2023 at a CAGR of 11.52%   during forecast period 2017 to 2023. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/1323 Test the market data and market information presented through more than 45 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Diabetes treatment and prevention market Research Report –BRICS Forecast to 2023.” BRICS diabetes treatment and prevention market players: Key players in diabetes treatment...
Post a Comment
Read more

Fluoroscopy and Mobile C-Arms Market is Substantially Gaining at a CAGR of 4.58% During Forecast to 2023

Market Overview: The increasing prevalence of chronic diseases is expected to have a significant impact on the fluoroscopy and mobile c-arms market. The market is also being encouraged by the massive geriatric population present globally. The increased pace of development in the healthcare sector is also anticipated to motivate the fluoroscopy and mobile c-arms market in the coming forecast period. Get a Free Sample @ https://www.marketresearchfuture.com/sample_request/7717 Fluoroscopy can be defined as an imaging technique, which uses X-Ray technology for taking real-time images of the body. It allows the physicians to visualize muscles, organs, and bones, which further helps them to make crucial decisions during surgery. The global Fluoroscopy And Mobile C-Arms Market Growth as per a report by Market Research Future (MRFR) is touted to register a CAGR of 4.58%, surpassing a valuation of USD 2,951.4 million during the forecast period. Competitive Dashboard: Canon Medical ...
Post a Comment
Read more